Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Moksi · 1 trial · 1 indication
maximum plasma concentration of Moxifloxacin
Area under plasma concentration time curve from zero to time of the last measurable concentration
area under the plasma concentration-time curve from zero to infinity.
| Arm | Type | Description |
|---|---|---|
| Moksi® 400mg Tablet of Abbott | EXPERIMENTAL | Healthy subjects were orally administered a single dose of Moksi® 400mg Tablet (Moxifloxacin) under fasting condition |
| Avelox® 400mg Tablet of Bayer | ACTIVE_COMPARATOR | Healthy subjects were orally administered a single dose of Avelox® 400mg Tablet (Moxifloxacin) under fasting condition. |
| Name | Type | Description |
|---|---|---|
| Moksi® 400mg Tablet | DRUG | Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast. |
| Drug: Avelox® 400Mg Tablet | DRUG | Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast. |
Inclusion Criteria: 1. Healthy male volunteers aged 18 to 55 years inclusive. 2. Subjects with a body mass index from 18.5 to 30 kg/m2 (both inclusive). 3. Subjects who are healthy as determined by routine physical examination,including vital sign monitoring (ie, blood pressure, heart rate,and temp...
Moksi is a small molecule drug being developed by Abbott Laboratories for bioequivalence. It is being studied as a 400mg tablet formulation to compare with Avelox 400mg tablet (moxifloxacin) under fasting conditions in healthy adult subjects. The drug is currently in Phase 1 clinical development.
Moksi is being developed by Abbott Laboratories, a company traded on the stock exchange under the ticker ABT. The drug is currently in Phase 1 clinical development for bioequivalence purposes.
Moksi is in Phase 1 clinical development. It is an investigational drug being studied for bioequivalence. A Phase 1 clinical trial has been completed to evaluate its bioequivalence compared to Avelox 400mg tablet (moxifloxacin) under fasting conditions.
Moksi has one completed clinical trial registered under NCT05307614. This Phase 1 study evaluated the bioequivalence of Moksi 400mg tablet and Avelox 400mg tablet (moxifloxacin) under fasting conditions in healthy adult Pakistani subjects. The trial enrolled 38 male participants.
Moksi is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied for bioequivalence, and a Phase 1 clinical trial has been completed, but it has not yet received regulatory approval.